A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Ev
Research payments
$388,063
Through program year 2022, $388,063 in research payments was reported against A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Ev, across 131 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $4,880 | 5 |
| 2021 | Research | $46,022 | 11 |
| 2020 | Research | $92,619 | 44 |
| 2019 | Research | $244,541 | 71 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Christopher Bowlus Sacramento, CA Named on 25 payments
- Kris Kowdley Seattle, WA Named on 22 payments
- Mangesh Pagadala Dallas, TX Named on 17 payments
- Elizabeth Verna New York, NY Named on 14 payments
- Elizabeth Carey Scottsdale, AZ Named on 8 payments
- Marlyn Mayo Dallas, TX Named on 8 payments
- Stuart Gordon Detroit, MI Named on 6 payments
- David Bernstein Staten Island, NY Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.